Chimiothérapie : Libre accès
Libre accès

Abstrait

New & Emerging Drugs for Squamous Cell Lung Cancer

Janaki Sharma and Haiying Cheng

Lung Cancer is the leading cause of cancer-related death worldwide. Squamous cell lung cancer (SQCLC) is the second most common histology (20-30% of cases) among non-small cell lung cancers (NSCLC), yet the treatment options remain limited [1]. The current standard for first line treatment of advanced or metastatic SQCLC consists of mainly platinum based chemotherapy. Recently, necitumumab in combination with platinum based doublet therapy was approved as front-line therapy. Second line options until recently included docetaxel, gemcitabine, nab-paclitaxel and erlotinib. Now newer agents including afatinib, ramucirumab/docetaxel, nivolumab and pembrolizumab are also available with superior clinical benefits